Brought to you by 
United Therapeutics gets rights to use Ascendis Pharma's TransCon technology; terminated
31 Dec 2014
Executive Summary
United Therapeutics Corp. (hypertension, cancer, and infectious disease treatments) has licensed exclusive rights to use Ascendis Pharma AS’s (improves existing drugs with its linker platform) TransCon technology to deliver Remodulin (treprostinil) for pulmonary arterial hypertension (PAH).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
United Therapeutics gets rights to use Ascendis Pharma's TransCon technology; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice